AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

23andMe Holding Co. (ME)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.72

0.00 (0.00%)

At close: Feb 20, 2025, 3:59 PM

2.74

0.74%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	2.67
Market Cap	72.97M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-17.39
PE Ratio (ttm)	-0.16
Forward PE	n/a
Analyst	Hold

Ask	2.83
Volume	187,894
Avg. Volume (20D)	252,533
Open	2.90
Previous Close	2.72
Day's Range	2.69 - 2.96
52-Week Range	2.42 - 13.74
Beta	undefined

About ME

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact respo...

[Show more]

Industry Medical - Diagnostics & Research

Sector Healthcare

IPO Date Nov 23, 2020

Employees 560

Stock Exchange NASDAQ

Ticker Symbol ME

Website https://www.23andme.com

Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for ME stock is "Hold." The 12-month stock price forecast is $9.4, which is an increase of 245.59% from the latest price.

Buy 0.00%

Hold 100.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

3 months ago

-21.47%

23andMe shares are trading lower. The stock may be... Unlock content with Pro Subscription

4 months ago

-2.67%

23andMe shares are trading lower. The company announced a 1-for-20 reverse stock split, effective October 16.

News

3 weeks ago · cnbc.com

23andMe is exploring strategic alternatives, looking to raise capital

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year.

1 month ago · pymnts.com

23andMe Reportedly Considers Selling Lemonaid Telehealth Unit

23andMe is reportedly considering the sale of Lemonaid Health, its telehealth operation. The consumer genetic testing kit company acquired Lemonaid in 2021 for $400 million and is now weighing a sale,...

1 month ago · businessinsider.com

23andMe has been quietly exploring a possible sale of its telehealth business, Lemonaid

23andMe has been exploring a possible sale of its telehealth business, Business Insider has learned. The struggling health company bought virtual care startup Lemonaid in 2021 for $400 million.